Skin Cancer
Topical DNA oligonucleotide therapy reduces UV-related mutagenesis
Published in Gene Therapy Weekly, May 20th, 2004
According to a study from the United States, "UV-induced DNA damage gives rise to mutations and skin cancer. We have previously reported that treatment of skin cells in vitro with thymidine dinucleotide (pTT) activates p53 and increases the ability of cells to repair subsequent UV-induced DNA damage by enhancing endogenous DNA repair capacity.
"Here we show that topical pTT pretreatment enhances the rate of DNA photoproduct removal, decreases UV-induced mutations, and reduces photocarcinogenesis in UV-irradiated hairless WT repair-proficient and Xpc+/- heterozygous partially...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-05-20)
More Articles from Gene Therapy Weekly
- Adverse Drug Effects
Long-term studies show transduced stem cells do not cause leukemia - Cancer Prevention
Upregulated heat shock protein 70 protects against tumor growth in mice - Diagnostics
A new semiquantitative assay explores the angiogenic potential of genes - Gene Suppression
Interleukin-12 gene therapy changes gene expression to block cancer growth - Immunology
Interleukin-12 gene therapy and 4-1BB costimulation drive melanoma eradication - Antitumor Effects
Magnaese superoxide dismutase mutant has potent antitumor effects - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
